Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 232 publications
Author Reply: Re-Evaluating the Impact of KRAS Mutations in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 05, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
Journal: JAMA oncology
Published: June 04, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 26, 2026
Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.
Journal: medRxiv : the preprint server for health sciences
Published: May 25, 2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 24, 2026
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 22, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 17, 2026
An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation study.
Journal: medRxiv : the preprint server for health sciences
Published: March 23, 2026
KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.
Journal: Cancer treatment reviews
Published: March 21, 2026
Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 16, 2026
Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 16, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2026
Last Updated: 09/26/2026